Treatment of painful bone lesions and hypercalcemia

E. Ascari, G. Attardo-Parrinello, G. Merlini

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The control of myeloma bone disease has been an important therapeutic problem. Bisphosphonates are potentially active for the control of myeloma bone resorption. Athough several studies proved the efficacy of short-term bisphosphonate treatment in inhibiting myeloma bone destruction, data on the long-term efficacy are scanty. We present the results of a prospective pilot study for the evaluation of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate) in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/d i.v. for 7 days followed by 100 mg/d i.m. for 10 d, administered at a mean interval of 4 months. The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients treated with chemotherapy only: Clodronate provided a significant np <0.001) reduction in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures. The results of this prospective pilot trial indicate that supportive long-term treatment with parenteral Clodronate can contribute significantly to controlling the progression of myeloma bone disease.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalEuropean Journal of Haematology, Supplement
Volume43
Issue number51
Publication statusPublished - 1989

Fingerprint

Clodronic Acid
Hypercalcemia
Bone and Bones
Bone Diseases
Diphosphonates
Bone Resorption
Therapeutics
Pain
Spontaneous Fractures
Prospective Studies
Morbidity
Drug Therapy
Control Groups
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of painful bone lesions and hypercalcemia. / Ascari, E.; Attardo-Parrinello, G.; Merlini, G.

In: European Journal of Haematology, Supplement, Vol. 43, No. 51, 1989, p. 135-139.

Research output: Contribution to journalArticle

Ascari, E, Attardo-Parrinello, G & Merlini, G 1989, 'Treatment of painful bone lesions and hypercalcemia', European Journal of Haematology, Supplement, vol. 43, no. 51, pp. 135-139.
Ascari, E. ; Attardo-Parrinello, G. ; Merlini, G. / Treatment of painful bone lesions and hypercalcemia. In: European Journal of Haematology, Supplement. 1989 ; Vol. 43, No. 51. pp. 135-139.
@article{52ecb355254e46f4ab160850a2e3ae4e,
title = "Treatment of painful bone lesions and hypercalcemia",
abstract = "The control of myeloma bone disease has been an important therapeutic problem. Bisphosphonates are potentially active for the control of myeloma bone resorption. Athough several studies proved the efficacy of short-term bisphosphonate treatment in inhibiting myeloma bone destruction, data on the long-term efficacy are scanty. We present the results of a prospective pilot study for the evaluation of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate) in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/d i.v. for 7 days followed by 100 mg/d i.m. for 10 d, administered at a mean interval of 4 months. The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients treated with chemotherapy only: Clodronate provided a significant np <0.001) reduction in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures. The results of this prospective pilot trial indicate that supportive long-term treatment with parenteral Clodronate can contribute significantly to controlling the progression of myeloma bone disease.",
author = "E. Ascari and G. Attardo-Parrinello and G. Merlini",
year = "1989",
language = "English",
volume = "43",
pages = "135--139",
journal = "Scandinavian journal of haematology. Supplementum",
issn = "0902-4506",
publisher = "Wiley-Blackwell",
number = "51",

}

TY - JOUR

T1 - Treatment of painful bone lesions and hypercalcemia

AU - Ascari, E.

AU - Attardo-Parrinello, G.

AU - Merlini, G.

PY - 1989

Y1 - 1989

N2 - The control of myeloma bone disease has been an important therapeutic problem. Bisphosphonates are potentially active for the control of myeloma bone resorption. Athough several studies proved the efficacy of short-term bisphosphonate treatment in inhibiting myeloma bone destruction, data on the long-term efficacy are scanty. We present the results of a prospective pilot study for the evaluation of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate) in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/d i.v. for 7 days followed by 100 mg/d i.m. for 10 d, administered at a mean interval of 4 months. The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients treated with chemotherapy only: Clodronate provided a significant np <0.001) reduction in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures. The results of this prospective pilot trial indicate that supportive long-term treatment with parenteral Clodronate can contribute significantly to controlling the progression of myeloma bone disease.

AB - The control of myeloma bone disease has been an important therapeutic problem. Bisphosphonates are potentially active for the control of myeloma bone resorption. Athough several studies proved the efficacy of short-term bisphosphonate treatment in inhibiting myeloma bone destruction, data on the long-term efficacy are scanty. We present the results of a prospective pilot study for the evaluation of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate) in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/d i.v. for 7 days followed by 100 mg/d i.m. for 10 d, administered at a mean interval of 4 months. The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients treated with chemotherapy only: Clodronate provided a significant np <0.001) reduction in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures. The results of this prospective pilot trial indicate that supportive long-term treatment with parenteral Clodronate can contribute significantly to controlling the progression of myeloma bone disease.

UR - http://www.scopus.com/inward/record.url?scp=0024930905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024930905&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 135

EP - 139

JO - Scandinavian journal of haematology. Supplementum

JF - Scandinavian journal of haematology. Supplementum

SN - 0902-4506

IS - 51

ER -